Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 160.00 Cr. (Dec 2024) to 198.00 Cr., marking an increase of 38.00 Cr..
For Expenses, as of Mar 2025, the value is 179.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Dec 2024) to 179.00 Cr., marking an increase of 34.00 Cr..
For Operating Profit, as of Mar 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Dec 2024) to 19.00 Cr., marking an increase of 4.00 Cr..
For OPM %, as of Mar 2025, the value is 9.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 9.00%.
For Other Income, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 1.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
For Depreciation, as of Mar 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Dec 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
For Profit before tax, as of Mar 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Dec 2024) to 17.00 Cr., marking an increase of 4.00 Cr..
For Tax %, as of Mar 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Dec 2024) to 28.00%, marking an increase of 6.00%.
For Net Profit, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Dec 2024) to 12.00 Cr., marking an increase of 2.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 2.49. The value appears strong and on an upward trend. It has increased from 2.06 (Dec 2024) to 2.49, marking an increase of 0.43.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:58 pm
Metric
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
266
284
326
206
238
321
307
432
487
527
647
662
Expenses
242
253
289
183
220
291
284
387
439
476
571
601
Operating Profit
24
31
38
23
18
30
23
45
47
52
76
61
OPM %
9%
11%
12%
11%
8%
9%
8%
10%
10%
10%
12%
9%
Other Income
4
5
4
8
7
5
4
11
5
6
12
9
Interest
1
1
1
1
0
1
1
2
2
1
1
1
Depreciation
2
3
2
2
2
2
7
15
12
10
9
9
Profit before tax
25
32
38
28
23
32
19
39
39
47
78
61
Tax %
31%
31%
32%
27%
29%
28%
25%
26%
22%
24%
23%
22%
Net Profit
18
22
26
20
17
23
14
28
31
36
60
47
EPS in Rs
3.51
4.39
5.15
4.00
3.30
4.66
2.86
5.68
6.10
7.22
11.99
9.45
Dividend Payout %
37%
27%
24%
31%
42%
29%
48%
26%
29%
28%
21%
16%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
22.22%
18.18%
-23.08%
-15.00%
35.29%
-39.13%
100.00%
10.71%
16.13%
66.67%
-21.67%
Change in YoY Net Profit Growth (%)
0.00%
-4.04%
-41.26%
8.08%
50.29%
-74.42%
139.13%
-89.29%
5.41%
50.54%
-88.33%
Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
9%
5 Years:
17%
3 Years:
11%
TTM:
2%
Compounded Profit Growth
10 Years:
9%
5 Years:
29%
3 Years:
18%
TTM:
-9%
Stock Price CAGR
10 Years:
4%
5 Years:
12%
3 Years:
32%
1 Year:
-10%
Return on Equity
10 Years:
15%
5 Years:
16%
3 Years:
16%
Last Year:
15%
Last Updated: Unknown
No data available for the Balance Sheet data table.
Reserves and Borrowings Chart
Cash Flow
Month
Month
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Cash from Operating Activity +
15
19
16
26
2
7
49
-19
29
54
13
37
Cash from Investing Activity +
-5
-12
-5
-20
2
3
-77
52
-8
-43
1
-20
Cash from Financing Activity +
-8
-8
-9
-4
-5
-7
22
-33
-19
-12
-9
-5
Net Cash Flow
2
-1
2
2
-1
3
-5
0
2
-2
5
12
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
82
102
88
84
100
109
85
96
90
102
118
107
Inventory Days
43
33
27
35
72
64
64
98
90
77
66
57
Days Payable
86
102
79
77
102
105
89
166
133
117
139
105
Cash Conversion Cycle
39
33
36
42
70
68
61
28
48
62
46
58
Working Capital Days
45
42
43
51
79
83
70
44
68
70
61
68
ROCE %
26%
31%
33%
35%
19%
14%
19%
10%
16%
18%
19%
26%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Promoters
70.43%
70.59%
70.59%
70.59%
70.59%
70.59%
70.59%
69.94%
69.91%
69.91%
69.91%
69.91%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.03%
0.03%
0.02%
0.02%
DIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.10%
0.00%
0.00%
0.00%
Public
29.56%
29.42%
29.41%
29.40%
29.40%
29.39%
29.40%
30.05%
29.96%
30.05%
30.06%
30.06%
No. of Shareholders
21,123
20,740
20,452
20,470
19,969
19,423
19,066
20,519
22,237
23,494
23,910
24,048
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund.
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
FaceValue
5.00
5.00
5.00
5.00
5.00
Basic EPS (Rs.)
9.45
11.98
7.22
6.10
5.67
Diluted EPS (Rs.)
9.45
11.98
7.22
6.10
5.67
Cash EPS (Rs.)
11.19
13.70
9.15
8.48
8.68
Book Value[Excl.RevalReserv]/Share (Rs.)
65.06
58.11
48.14
42.66
38.04
Book Value[Incl.RevalReserv]/Share (Rs.)
65.06
58.11
48.14
42.66
38.04
Dividend / Share (Rs.)
1.50
2.50
2.00
1.75
1.50
Revenue From Operations / Share (Rs.)
132.01
129.11
105.26
97.11
86.20
PBDIT / Share (Rs.)
14.04
17.41
11.45
10.39
11.00
PBIT / Share (Rs.)
12.30
15.70
9.52
8.00
7.99
PBT / Share (Rs.)
12.17
15.63
9.47
7.81
7.69
Net Profit / Share (Rs.)
9.45
11.98
7.22
6.10
5.67
PBDIT Margin (%)
10.63
13.48
10.87
10.69
12.76
PBIT Margin (%)
9.31
12.15
9.04
8.23
9.27
PBT Margin (%)
9.22
12.10
8.99
8.03
8.92
Net Profit Margin (%)
7.15
9.28
6.85
6.27
6.58
Return on Networth / Equity (%)
14.52
20.62
14.99
14.29
14.91
Return on Capital Employeed (%)
18.78
26.84
19.57
18.53
20.73
Return On Assets (%)
9.34
13.47
8.93
8.80
8.54
Total Debt / Equity (X)
0.03
0.01
0.00
0.01
0.07
Asset Turnover Ratio (%)
1.39
1.52
1.40
1.43
1.31
Current Ratio (X)
2.11
2.20
1.91
1.98
1.70
Quick Ratio (X)
1.69
1.71
1.46
1.37
1.12
Inventory Turnover Ratio (X)
6.18
6.62
4.94
4.36
4.53
Dividend Payout Ratio (NP) (%)
0.00
16.68
24.23
24.59
0.00
Dividend Payout Ratio (CP) (%)
0.00
14.60
19.11
17.67
0.00
Earning Retention Ratio (%)
0.00
83.32
75.77
75.41
0.00
Cash Earning Retention Ratio (%)
0.00
85.40
80.89
82.33
0.00
Interest Coverage Ratio (X)
113.62
246.74
262.77
54.16
36.88
Interest Coverage Ratio (Post Tax) (X)
77.46
170.85
166.66
32.80
20.03
Enterprise Value (Cr.)
736.68
1223.09
392.34
417.88
446.02
EV / Net Operating Revenue (X)
1.11
1.89
0.74
0.85
1.03
EV / EBITDA (X)
10.47
14.02
6.84
8.03
8.09
MarketCap / Net Operating Revenue (X)
1.13
1.90
0.75
0.88
1.05
Retention Ratios (%)
0.00
83.31
75.76
75.40
0.00
Price / BV (X)
2.29
4.23
1.65
2.01
2.37
Price / Net Operating Revenue (X)
1.13
1.90
0.75
0.88
1.05
EarningsYield
0.06
0.04
0.09
0.07
0.06
After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
For Diluted EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
For Cash EPS (Rs.), as of Mar 25, the value is 11.19. This value is within the healthy range. It has decreased from 13.70 (Mar 24) to 11.19, marking a decrease of 2.51.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 24) to 1.50, marking a decrease of 1.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 132.01. It has increased from 129.11 (Mar 24) to 132.01, marking an increase of 2.90.
For PBDIT / Share (Rs.), as of Mar 25, the value is 14.04. This value is within the healthy range. It has decreased from 17.41 (Mar 24) to 14.04, marking a decrease of 3.37.
For PBIT / Share (Rs.), as of Mar 25, the value is 12.30. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.30, marking a decrease of 3.40.
For PBT / Share (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has decreased from 15.63 (Mar 24) to 12.17, marking a decrease of 3.46.
For Net Profit / Share (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
For PBDIT Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has decreased from 13.48 (Mar 24) to 10.63, marking a decrease of 2.85.
For PBIT Margin (%), as of Mar 25, the value is 9.31. This value is below the healthy minimum of 10. It has decreased from 12.15 (Mar 24) to 9.31, marking a decrease of 2.84.
For PBT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 12.10 (Mar 24) to 9.22, marking a decrease of 2.88.
For Net Profit Margin (%), as of Mar 25, the value is 7.15. This value is within the healthy range. It has decreased from 9.28 (Mar 24) to 7.15, marking a decrease of 2.13.
For Return on Networth / Equity (%), as of Mar 25, the value is 14.52. This value is below the healthy minimum of 15. It has decreased from 20.62 (Mar 24) to 14.52, marking a decrease of 6.10.
For Return on Capital Employeed (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has decreased from 26.84 (Mar 24) to 18.78, marking a decrease of 8.06.
For Return On Assets (%), as of Mar 25, the value is 9.34. This value is within the healthy range. It has decreased from 13.47 (Mar 24) to 9.34, marking a decrease of 4.13.
For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
For Asset Turnover Ratio (%), as of Mar 25, the value is 1.39. It has decreased from 1.52 (Mar 24) to 1.39, marking a decrease of 0.13.
For Current Ratio (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.11, marking a decrease of 0.09.
For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.69, marking a decrease of 0.02.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.18. This value is within the healthy range. It has decreased from 6.62 (Mar 24) to 6.18, marking a decrease of 0.44.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 16.68 (Mar 24) to 0.00, marking a decrease of 16.68.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 14.60 (Mar 24) to 0.00, marking a decrease of 14.60.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 83.32 (Mar 24) to 0.00, marking a decrease of 83.32.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 85.40 (Mar 24) to 0.00, marking a decrease of 85.40.
For Interest Coverage Ratio (X), as of Mar 25, the value is 113.62. This value is within the healthy range. It has decreased from 246.74 (Mar 24) to 113.62, marking a decrease of 133.12.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 77.46. This value is within the healthy range. It has decreased from 170.85 (Mar 24) to 77.46, marking a decrease of 93.39.
For Enterprise Value (Cr.), as of Mar 25, the value is 736.68. It has decreased from 1,223.09 (Mar 24) to 736.68, marking a decrease of 486.41.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.11, marking a decrease of 0.78.
For EV / EBITDA (X), as of Mar 25, the value is 10.47. This value is within the healthy range. It has decreased from 14.02 (Mar 24) to 10.47, marking a decrease of 3.55.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 83.31 (Mar 24) to 0.00, marking a decrease of 83.31.
For Price / BV (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.23 (Mar 24) to 2.29, marking a decrease of 1.94.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Anuh Pharma Ltd as of June 26, 2025 is: 179.02
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, Anuh Pharma Ltd is Overvalued by 14.34% compared to the current share price 209.00
Intrinsic Value of Anuh Pharma Ltd as of June 26, 2025 is: 198.21
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, Anuh Pharma Ltd is Overvalued by 5.16% compared to the current share price 209.00
Last 5 Year EPS CAGR: 10.72%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 14.52% (Industry Average ROE: 15.19%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 22.2 (Industry average Stock P/E: 103.22)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.03
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Anuh Pharma Ltd. is a Public Limited Listed company incorporated on 19/02/1960 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1960PLC011586 and registration number is 011586. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 661.51 Cr. and Equity Capital is Rs. 25.06 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Anuh Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
